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Abstract
Amongst all the internal gene segments (PB2. PB1, PA, NP, M and NS), the avian PB1 segment is the only one which was
reassorted into the human H2N2 and H3N2 pandemic strains. This suggests that the reassortment of polymerase subunit
genes between mammalian and avian influenza viruses might play roles for interspecies transmission. To test this
hypothesis, we tested the compatibility between PB2, PB1, PA and NP derived from a H5N1 virus and a mammalian H1N1
virus. All 16 possible combinations of avian-mammalian chimeric viral ribonucleoproteins (vRNPs) were characterized. We
showed that recombinant vRNPs with a mammalian PB2 and an avian PB1 had the strongest polymerase activities in human
cells at all studied temperature. In addition, viruses with this specific PB2-PB1 combination could grow efficiently in cell
cultures, especially at a high incubation temperature. These viruses were potent inducers of proinflammatory cytokines and
chemokines in primary human macrophages and pneumocytes. Viruses with this specific PB2-PB1 combination were also
found to be more capable to generate adaptive mutations under a new selection pressure. These results suggested that the
viral polymerase activity might be relevant for the genesis of influenza viruses of human health concern.
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Introduction
Influenza A viruses with all 16 haemagglutinin (HA) and 9
neuraminidase (NA) subtypes can be isolated from aquatic avian
species and this avian viral gene pool is believed to be responsible
for the genesis of pandemic viruses [1,2,3]. There were three
human influenza pandemics in the last century. The pandemic
1918 H1N1 virus was suggested to be of avian origin [4,5,6]. By
contrast, the 1957 H2N2 and 1968 H3N2 viruses acquired the
surface protein(s) (H2 and N2 for H2N2; H3 for H3N2) and
polymerase basic 1 (PB1) gene segments from avian strains [7].
Previous studies revealed that the HA and NA surface proteins
might play key roles on the zoonotic transmission of influenza
virus [8,9]. Other studies suggested that the host-range specificity
of influenza virus is a multigenic trait [10,11,12,13].
The emergence of highly pathogenic (HP) H5N1 avian
influenza virus, with its ability to infect humans, has caused
serious pandemic concerns [14,15]. The virus was initially
confined to Asia, but it has spread to different continents over
the last few years [16,17,18]. Thus far, these viruses caused more
than 400 confirmed human H5 cases [19] and prompted several
mass culling of poultry. The mortality rate of human H5 infections
is over 60%. The remarkable disease severity of H5 infections
might be partly explained by its ability to provoke exaggerated
proinflammatory cytokine and chemokine expressions
[20,21,22,23]. Currently, H5 viruses can only be transmitted
between humans with a very limited efficiency, indicating that
these viruses still do not fully adapt to humans. However, with the
experiences learnt from the last 3 pandemics, these H5 viruses or
other viral subtypes might gain this ability by introducing adaptive
mutations or by reassorting with a human virus.
Growing evidences suggested that the influenza viral trimeric
polymerase complex formed by polymerase basic 2 (PB2),
polymerase basic 1 (PB1), and polymerase acid (PA) might be
associated with viral virulence and/or interspecies transmission
[11,24,25,26,27,28]. Previous studies revealed that the viral
polymerase subunits from human isolates might not be fully
compatible to those isolated from avian strains [29]. Others
further identified that some residues in these polymerase subunits
might control host-restriction [29,30,31,32,33]. The amino acid
position 627 in the PB2 protein was shown to be a critical
determinant for viral virulence and host specificity [31,34,35,36].
Interestingly, of all the internal protein gene segments, avian PB1
is the only segment that was reassorted into the human H2N2 and
H3N2 viruses. These recurrent events suggested that the
acquisition of avian PB1 segment might pose biological advantages
to the reassorted viruses. However, the underlying reason for the
repeat introductions of avian PB1 into the human viruses is still an
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5658
enigma. The N- and C-terminal regions of PB1 interact with PA
and PB2, respectively, to form a heterotrimeric polymerase
complex [37,38,39,40,41,42,43]. In addition, PB1 contains
conserved RNA-dependent RNA polymerase motifs, nucleotide
binding domains, and viral/complementary RNA (vRNA/cRNA)
binding sites [44]. Therefore, it was hypothesized that the
reassortments of viral polymerase genes in the pandemic H2 and
H3 might modulate the viral polymerase activity, thereby helping
the progeny viruses to adapt to humans [45,46].
In this study, we investigated the compatibility of viral
polymerase subunits isolated from a mammalian H1 virus and
an avian H5 virus. Specifically, it is of our interest to determine
whether recombinant viruses with enhanced viral polymerase
activity might have any implications to human infections.
Materials and Methods
Cells and viruses
Primary chicken embryonic fibroblasts (CEF) were prepared
from specific pathogen free embryonic eggs (Jinan Spafas Poultry
Co, Ltd). CEF, 293T human embryonic kidney cells and Madin-
Darby canine kidney (MDCK) cells were maintained in minimum
essential medium (MEM) supplemented with 10% fetal calf serum
(FCS), 1% penicillin, and 1% streptomycin at 37uC. Primary
human monocyte-derived macrophages were prepared as de-
scribed [20]. The differentiated macrophages were cultured in
Macrophage Serum Free medium (MSFM, Invitrogen) for one
day prior to viral infections. Primary human alveolar epithelial
cells (type I pneumocytes) were isolated from patient non-tumor
lung tissues as described [23].
All viruses studied in this investigation were synthetically
generated by reverse genetic techniques. Indo5 is a clade 2.1
H5N1 virus and does not transmit efficiently in mammals [47].
Viral infections
Cells infected at multiplicities of infection (MOI) of 0.01 and 2
were used to study virus replication kinetic and cytokine expression
profiling, respectively. After one hour of virus absorption, the virus
inoculums were washed out and replaced with MEM supplement-
ed with 0.5% FCS (for MDCK), MSFM (for primary macrophage)
or small airway growth medium (for pneumocytes; Cambrex
Bioscience Walkersville). All viral culture media were supplement-
ed with 0.6 mg/L penicillin, 60 mg/L streptomycin, and 2 mg/L
N-p-tosyl-L-phnylalanine chloromethyl ketone (TPCK) treated
trypsin (Sigma). The infectivity of the studied viruses were
confirmed by staining representative infected cells with anti-NP
immunofluorescence antibody (Imagen, oxoid, UK)
Generation of recombinant influenza viruses
Recombinant virues were generated by reverse genetic
techniques [48]. The identities of these viruses or the introduced
mutations were confirmed by sequencing. Viral titres were
determined by routine plaque assays. Experiments involving
infectious recombinant viruses were conducted in biological safety
level 3 facilities.
Expression of recombinant vRNPs
Plasmids expressing WSN PB2, PB1, PA and NP proteins
(pcDNA-WSN-PB2, pcDNA-WSN-PB1, pcDNA-WSN-PA,
pcDNA-WSN-NP) and WSN NA vRNA (pPolI-NA-RT) were
used to generate recombinant RNPs as described [49]. Briefly,
1 mg of each of the plasmids was transfected into 293T cells by
Lipofectamine 2000 (Invitrogen) as instructed by the manufactur-
er. The medium of transfected cells was replaced by MEM with
10% FCS and 1% P/S at 6 hours post-transfection. For the
luciferase reporter assay (see below), a model luciferase vRNA
expression plasmid (pPolI-Luc-RT) modified from pPolI-NS [49]
was used to replace pPolI-NA-RT in the transfection.
For expressing chimeric avian-mammalian vRNPs, the corre-
sponding genes from Indo5 were subcloned into pcDNA-3A
(pcDNA-Indo5-PB2 pcDNA-Indo5-PB1, pcDNA-Indo5-PA and
pcDNA-Indo5-NP) as described [49].
Luciferase assay for viral polymerase activities
Various combinations of PB2, PB1, PA and NP protein
expression plasmids and the pPolI-Luc-RT were transfected into
293T cells [50]. In addition, a GFP expression plasmid was also
co-transfected into the cells and the GFP signals from the
transfected cells were used to normalize the data. Initial
experiments showed that data with or without the normalization
are comparable. For determining the polymerase activities of these
recombinant vRNPs in avian cells, the human PolI promoter
sequence of pPolI-Luc-RT was replaced by a CEF derived PolI
promoter sequence as described [51]. At 48 hours post-infection,
treated cells were lysed by Steady-Glo assay reagent (Promega) for
5 minutes and the luminescence was measured by a luminometer
(Victor3, PerkinElmer). All data and standard deviations were
determined from three independent experiments.
RNA extraction and cDNA synthesis
Total RNA from transfected or infected cells were harvested by
using a RNeasy mini kit (Qiagen). Genomic DNA was digested by
DNase Turbo (Ambion) for 30 minutes prior to reverse-transcrip-
tion reactions. 1.5 mg of total RNA was reverse transcribed by
SuperScript II reverse transciptase (Invitrogen) and 10 pmol of
vRNA specific primer (59-AGCAAAAGCAGG-39) [52] or
50 pmol of oligo-dT primer was used in each reaction.
Primer extension assay
RNA from MDCK infected at a MOI of 2 was harvested at
6 hours post-infection. Primer extension was performed as
described previously [53]. Briefly, 1.5 mg of heat-denatured total
RNA was reversed transcribed in a reaction containing 6 pmol of
fluorescent primer (59-Cy3-TGGACTAGTGGGAGCATCAT-39
for NA vRNA or 59-Cy5-TCCAGTATGGTTTTGATTTCCG-
39 for NA cRNA/mRNA), 50 U of SuperScript H RNase H-
reverse transcriptase (Invitrogen), 16 first-strand buffer (Invitro-
gen), 1 mM deoxynucleoside triphosphate and 20 mM dithiothre-
itol. Reactions were incubated at 45uC for 90 minutes. The
fluorescent products were resolved in 10% denaturing polyacryl-
amide gels and the images were analyzed by an imaging analyzer
(Typhoon 8600 variable mode imager, Amersham Biosciences).
For studying RNA from vRNP-expression cells, transfected cells
were harvested at 48 hours post-transfection.
Cytosol/nucleus fractionation
Nuclear proteins from transfected 293T cells were isolated by
incubating PBS washed cells in five times packed cell volume of
hypotonic buffer A (10 mM Hepes pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM DTT, and complete mini-EDTA-free
protease inhibitor cocktail tablet (Roche)) for 10 minutes on ice,
followed by passing the lysate through a 27G syringe for multiple
times [54]. The lysates were centrifuged at 1,000 g for 5 minutes
at 4uC and the pellet was resuspended with buffer S1 (0.25 M
sucrose and 10 mM MgCl2). The resuspended pellet was
overlayed on buffer S2 (0.35 M sucrose and 0.5 mM MgCl2),
followed by a centrifugation (1,500 g for 5 minutes at 4uC). The
Chimeric Influenza vRNPs
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pellet was washed with buffer S2, followed by a centrifugation at
1,500 g for 5 minutes at 4uC. The nuclear pellet was stored at
280uC until use.
Co-Immunoprecipitation
Plasmid pcDNA-PAtap, which expresses a TAP-tagged WSN
PA [55], was used to replace pcDNA-WSN-PA to generate TAP-
tagged RNPs. Transfected cells were treated with lysis buffer
[50 mM HEPEs, pH 8.0, 200 mM NaCl, 25% Glycerol, 0.5%
Igepal CA-630 [Sigma], 1 mM b-mercaptoethanol, 0.1 mM
PMSF, and complete mini-EDTA-free protease inhibitor cocktail
tablet (1 tablet/10 ml; Roche)] at 48 hours post-transfection. The
TAP-tagged PA and its interacting proteins were co-purified with
immunoglobinlin G-Sepharose (GE Healthcare) and washed with
binding buffer [10 mM HEPEs, pH8.0, 150 mM NaCl, 10%
Glycerol, 0.1% Igepal CA-630 (Sigma), and 0.1 mM phenyl-
methylsulfonyl fluoride]. The purified proteins were released to 26
SDS sampling loading buffer by boiling.
Western blot analysis
Proteins were resolved by 6–12% gradient SDS-polyacrylamide
gels and transferred to PVDF membranes (Amersham Bioscienc-
es). Proteins were analyzed by Western blotting using anti-Pol II
(N-20 and A-10, Santa Cruz Biotechnology), anti-phosphorylated
Pol II (8A7, Santa Cruz Biotechnology), anti-b-actin (C4, Santa
Cruz Biotechnology), anti-PB2 (PB2/20 and PB2/22) [56], anti-
PA [57] primary antibodies and the corresponding HRP-
conjugated secondary antibodies. Signals were detected by the
ECL Plus detection system as instructed (Amersham Biosciences).
Quantification of cytokine mRNA by real-time
quantitative RT-PCR
Total RNA from infected macrophages and pneumocytes were
analyzed by real-time PCR assays as described [20,23]. Cells were
infected at a MOI of 2 and total RNA was harvested at 3, 6 and
8 hours post-infections. The mRNA levels of TNF-a, interferon-b,
RANTES (regulated on activation, normal T cell expressed and
secreted) and IP-10 (interferon-gamma-inducible protein-10),
influenza M1 and beta-actin were determined.
ELISA assays
The concentrations of TNF-a, IP-10 and RANTES proteins
were measured by ELISA assays (R&D Systems, Minneapolis,
MN, USA). Samples were first irradiated with ultraviolet light
(CL-100 Ultra Violet Cross linker) for 15 min to inactivate any
infectious virus before the ELISA assays were done. Cytokine
protein levels in the samples and control standards were measured
as previously described by us [23]. Previous experiments had
confirmed that the dose of ultraviolet light used would not affect
cytokine concentrations as measured by ELISA [20].
Selection of oseltamivir-resistant recombinant viruses
MDCK cells infected at a MOI of 0.1 were treated with
oseltamivir at a concentration which can reduce the viral titre by
about 99%. Briefly, the wild type and the mutant were passaged in
MDCK cells in the presence of 1.52 nM of oseltamivir. In each
passage, cells were infected with the passaged viruses (,MOI of
0.1). At day 2 post-infection, the viral titre in the culture
supernatant was determined by plaque assays. Progeny viruses
from trial 1 (passage 7) and trial 2 (passage 6) were plaque purified.
To test the drug susceptibilities of the purified viruses, MDCK
cells infected with 0.1 MOI of these viruses were incubated with 2-
fold serially diluted oseltamivir in quadruplicate and the drug
concentration required for inhibiting 50% of cytopathic effect
(IC50) was determined at 48 hours post-infection.
Statistical analysis
Unless otherwise specified, all data were analyzed on a SPSS
platform (SPSS Inc., Chicago). The main and interaction effects of
various factors on viral polymerase activities were analyzed by full
factorial ANOVA (Univariate General Linear Model) with the log
transformed dataset. The statistically significant differences were
determined by t-test or Analysis of Variance followed by
Bonferroni Post hoc tests (p,0.05). Correlations were determined
with bivariate correlations procedures (Pearson’s correlation
coefficient, p,0.05).
Results
Compatibility between PB2, PB1, PA and NP from
mammalian and avian strains in human cells
To study the compatibility between avian and human PB2,
PB1, PA and NP at different temperature, we employed a full
factorial analytical approach to study these 5 independent factors
(i.e. temperature and origin of PB2, PB1, PA and NP). A H1N1
virus (A/WSN/33, WSN) and a H5N1 virus (A/Indonesia/5/05,
Indo5) were used as the prototype strains in the study. The WSN
PB2 contains a Lys at position 627, whereas Indo5 contains a Glu
at the same position. Recombinant vRNPs with all 16 possible
combinations were generated in transfected cells and the
polymerase activities of these vRNPs were determined by a
luciferase reporter assay (Fig. 1A). These mutants were hereafter
named according to the source of their genes in the order of PB2,
PB1, PA and NP (A: avian; M: mammalian). The readings were
then examined by using full factorial univariate Analysis of
Variance (ANOVA) so as to determine the relative importance of
these factors on influenza viral polymerase activities (Table S1). As
shown in Fig. 1A, the origins of PB2 and PB1 were found to have
significant effects on viral polymerase activities (F.500; P,0.001).
Recombinant vRNPs with either mammalian PB2 or avian PB1
were found to have higher polymerase activities than their
counterparts (e.g. compare MAAA vs AAAA and AAAA vs
AMAA). The results also agreed with previous findings [58,59]
that the incubation temperature has highly significant effects on
the viral polymerase activity (F = 271; P,0.001). By contrast, the
origins of NP and PA were found to be insignificant and
marginally significant (P,0.01; F,7), to the polymerase activity,
respectively. This analysis, however, did not exclude the possibility
that the origins of these PA and NP are critical for other virological
processes.
With these data, we tried to identify whether any of these 2
independent factors might have statistical ‘‘interaction’’ (i.e.
synergistic or antagonistic) effects on the viral polymerase activity.
Of all 10 possible combinations, 5 pairs (PB2-PB1, PB1-PA, PB2-
Temp, PB1-Temp and PA-Temp) were found to be statistically
significant (Table S1). Interestingly, a strong PB2-PB1 interaction
effect was observed (Table S1, compare the F values amongst these
pairs). This demonstrated that the compatibility between PB2 and
PB1 is critical to the polymerase activity. Indeed, recombinant viral
RNPs with the mammalian PB2-avian PB1 pair (Fig 1A. lanes 9–12)
were all found to have strong polymerase activities. By contrast, all
vRNPs with the avian PB2-mammalian PB1 pair had reduced
polymerase activities (lanes 5–8). These observations were con-
firmed by testing recombinant vRNPs derived from a clade 1 H5N1
virus (A/VN/1203/03) and the WSN (data not shown). Besides, a
relatively weak, but statistically significant, PB1-PA interaction
effect was observed. Viral RNPs with an avian PB1-PA pair were
Chimeric Influenza vRNPs
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found to have stronger polymerase activities than their counterparts
in most of the studied conditions. The above findings might be
partly explained by the fact that PB1 physically interacts with PB2
and PA for the formation of viral polymerase complex [60].
In addition to the statistical interaction effects between viral
polymerase subunits, the temperature-PB2, termperature-PB1 and
temperature-PA pairs were found to be statistically significant
(Table S1). As shown in Fig. 1A, except the vRNPs with the avian
PB2-mammalian PB1 pair (lanes 5–8), all the avian-mammalian
chimeric vRNPs had stronger polymerase activities than the WSN
control at 40uC. By contrast, except those with the mammalian
PB2-avian PB1 pair (Fig. 1A, lane 9–12), all of these recombinant
vRNPs were found to be less active than the WSN at 32uC. These
agreed with previous findings that human influenza viruses are
adapted to replicate in the upper respiratory tract at 33–37uC,
whereas avian influenza viruses prefer to replicate in the gut at
around 41uC [61,62]. It should be noted that the vRNPs with the
avian PB2-mammalian PB1 pair (Fig. 1A, lanes 5–8) and those
with the mammalian PB2-avian PB1 pair (Fig. 1A, lane 9–12) had
the weakest and strongest polymerase activities, respectively, at all
the studied temperature. These findings reiterated the dominant
roles of PB2-PB1 combinations in our experimental setting.
NA-specific primer extension assays were also used to detect NA
vRNA, cRNA and mRNA isolated from the transfected cells. Low
levels of NA vRNA and cRNA were detected from cells expressing
vRNPs with the avian PB2-mammalian PB1 pair (Fig. 1B, lanes 1–
4). The mRNA level of these samples was below the detection limit
of the assay. By contrast, recombinant vRNPs with the
mammalian PB2-avian PB1 pair were found to be very active
(Fig. 1B, lanes 5–8). In particular, the cRNA and mRNA
generated from these recombinant vRNPs were usually more
abundant that the WSN control (Fig. 1B, lane 9).
The above results showed that different combinations of PB2
and PB1 might have differential effects on the polymerase activity.
To elucidate the underlying mechanism account for this
phenomenon, we selected representative polymerase complexes
that have a strong (Fig. 1C, lane 4), moderate (Fig. 1C, lane 5) or
weak polymerase activity (Fig. 1C, lane 3) for further character-
izations. We first investigated the abundances of these trimeric
polymerase complexes formed in the nucleus. Nuclear proteins
from cells expressing different combinations of TAP-tagged
polymerase complex were immunoprecipitated with immunoglo-
binlin G-Sepharose. As shown in Fig. 1C, the amounts of TAP-PA
of these samples were similar. The PB2 signals from the reactions
with the avian PB2-avian PB1 pair (Fig. 1C, lane 5) and with the
mammalian PB2-avian PB1 pair (lane 4) were comparable to the
WSN control (Fig. 1C, lane 2). However, the PB2 signal from the
sample with the avian PB2-mammalian PB1 combination (Fig. 1C,
lane 3) was much reduced. These indicated that this specific PB2-
PB1 combination, together with PA, might be less capable of
forming heterotrimeric polymerase complexes.
Functional viral polymerase complexes were previously shown
to bind to the hyperphosphorylated form of RNA Polymerase II
(Pol IIo) [63]. We therefore detected the amount of vRNP-bound
Pol IIo in the nuclear fraction (Fig 1C, top panel). Interestingly, the
Pol IIo signal from the reaction with the mammalian PB2-avian
PB1 pair (Fig. 1C, lane 4) was much stronger than that of the
control (lane 2). By contrast, a reduced Pol IIo signal was observed
from the reaction with the avian PB2-mammalin PB1 pair (Fig. 1C,
lane 3). These results suggested the polymerase complex with the
mammalian PB2-avian PB1 combination might be more capable
to recruit cellular transcription machinery to initiate viral RNA
synthesis.
Some efforts had also been made to map the PB1 and PB2
regions that might modulate the polymerase activity. Chimeric
WSN-Indo5 PB1 proteins were generated (Fig. 2) and tested in the
luciferase reporter assay. Mutant 2 had a weak polymerase activity
in both vRNP backgrounds. As the N-terminal 1/3 of PB1
contains the ORF for PB1-F2 [64], results from the Mutant 2
suggested that the enhanced viral polymerase activity observed in
our study is unlikely due to the H5 PB1-F2 protein. The
polymerase activities of the Mutant 1, 3 and 4 were similar to or
better than the Indo5 wild-type control. Results from the Mutants
1 and 4 further suggested that both the middle 1/3 and C-terminal
1/3 of Indo5 PB1 can stimulate the polymerase activity. Using a
similar experimental design, the C-terminal 1/3 of mammalian
PB2 was found to responsible for the enhanced viral polymerase
activity (Fig. S1). As we primarily interested in studying the
implication of influenza polymerase activity on the viral infection,
we did not perform systematic mutagenic studies on these genes.
Compatibility between PB2, PB1, PA and NP from
mammalian and avian strains in avian cells
We also tested the compatibility of these polymerase subunits
and NP in chicken embryonic fibroblasts (Fig. 3). Using these data
and the equivalent data from the human cells (Fig. 1A, middle
panel), we performed statistical analysis to study the relative
importance of these factors (i.e. origins of PB2, PB1 PA, NP and
cells) on the viral polymerase activity. Of all these parameters, the
origin of PB1 was shown to have a prominent effect on the
polymerase activity (P,0.001) (Table S2). All recombinant vRNPs
with the avian PB1 were found to have higher luciferase activities
than their counterparts (e.g. compare lanes 9–12 to 13–16 in
Fig. 3). Moreover, the origin of cells (P = 0.014) and the origin of
PB2 (P = 0.01) was also found to affect the polymerase activity as
expected. For example, viral RNPs with an avian PB2 were shown
to have much stronger polymerase activities in CEF (Fig. 3, lanes
1–4), but not in human cells (Fig. 1A, lanes 1–4) (P,0.05). These
phenomena might be explained by the Lys/Glu polymorphism at
position 627 of these PB2 [59]. Because of this cell-type effect, the
effect of PB2-PB1 combination on the polymerase activity was not
considered to be statistically significant in this dataset (Table S2).
Nonetheless, viral RNPs with the mammalian PB2-avian PB1 pair
(Fig. 3, lanes 9–12) and with the avian PB2-mammalian PB1 pair
(Fig. 3, lanes 5–8) still had the strongest and lowest polymerase
activities, respectively, in avian cells. Taken all these together, our
data demonstrated that both the origin of PB2 and the origin of
PB1 might be critical for viral RNA synthesis in our experimental
setting. Specifically, vRNPs with a mammalian PB2 and an avian
Figure 1. Characterization of recombinant vRNPs generated from transfected cells. The origins of PB2, PB1, PA and NP in each
recombinant vRNP were as shown (A= avian, M=mammalian). A) Luciferase reporter assay for influenza viral polymerase activity. Polymerase
activities (mean6SE) of recombinant vRNPs in 293T cells incubated at 32uC (top panel), 37uC (middle panel) and 40uC (bottom panel). All data were
determined from three independent experiments. The polymerase activities of WSN were set as 100% as references. B) Detection of NA mRNA, cRNA,
and vRNA by primer extension assays. Signals for the mRNA, cRNA and vRNA were as shown. C) Immunoprecipitation of TAP-tagged PA. Nuclear
lysates expressing different combinations of chimeric viral polymerase complexes were immunoprecipitated by immunoglobinlin G-Sepharose. The
amounts of PB2 and Pol IIo coimmunoprecipitated with TAP-PA were determined by Western blot techniques.
doi:10.1371/journal.pone.0005658.g001
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PB1 were found to have strong viral polymerase activities in all the
studied conditions.
Generation of recombinant viruses with chimeric vRNPs
To elucidate the possible implications of the above findings to
the viral lifecycle, vRNP combinations with the strongest (Fig. 1A,
lanes 9–12) and weakest (Fig. 1A, lanes 5–8) polymerase activities
were introduced into recombinant viruses by reverse genetic
techniques. In addition, to avoid possible influences from the other
avian H5 genes (i.e. HA, NP, M and NS), these viruses were all
generated in a background of WSN. As shown in Fig. 4A, all
recombinant viruses with the avian PB2-mammalian PB1 pair had
small plaque phenotypes (t-test, P,0.05) (lanes 1–4). Mutants with
the avian PB2-mammalian PB1 pair (AMAA and AMMM) were
found to have a 2 log-unit reduction of viral titre when propagated
at 37uC (Fig. 4B). By contrast, the plaque sizes of the mutants with
the mammalian PB2-avian PB1 combination were all comparable
with that of WSN (Fig. 4A). Interestingly, the mammalian PB2-
avian PB1 vRNP-containing mutants (MAMM and MAAA)
reproducibly had slightly faster replication kinetics than the wild
type at the first studied post-infection time point (t-test, P,0.05).
The maximum viral titres of these two mutants in the subsequent
time points were similar to the wild-type control. But one should
not neglect the fact that, at the late stage of viral infection, other
factors might be the limiting factors for the virion productions
[65,66,67,68].
The growth kinetics of the MAMM mutant at different
temperature were also determined (Fig. S2). In all the studied
conditions, the viral titres of MAMM mutant were similar or much
higher than those of the WSN, demonstrating the MAMM virus
could replicate efficiently in a wild range of temperature. In
addition, our results also demonstrated that the Indo5 PB1 might
play an important role in facilitating the virus replication at high
temperature (Fig. S2).
To confirm whether the PB2-PB1 combination would have a
direct effect on viral RNA synthesis upon infection, viral RNA
generated from representative infected cells was subjected to the
NA-specific primer extension assays. As shown in Fig. 4C, viral
NA mRNA was highly expressed in MAMM-infected cells,
whereas the level of NA mRNA from AMMM infected cells was
below the detection limit of the assay. Similarly, the vRNA signal
from the AMMM-infected sample was weaker than those of the
MAMM sample and WSN control (MMMM). The cRNA signals
from these viruses were below the detection limit of the assay.
Apart from binding to cellular Pol IIo, influenza viral
polymerase was shown to reduce the hypophosophorylated Pol
II (Pol IIa) level in infected cells [69]. We therefore characterized
the protein expressions of Pol II (Pol IIa and Pol IIo) from infected
cell lysates. The levels of Pol IIa and Pol IIo in infected cells were
found to be reduced and enhanced, respectively (Fig. 4D).
Interestingly, the Pol IIo/Pol IIa ratio from the MAMM-infected
cell was shown to be much higher than that of the wild type. Given
the idea that Pol II phosphorylation is a dynamic event [70], our
data suggested that the rate of viral RNA synthesis might modulate
the phosphorylation status of Pol II. In addition, we consistently
observed a characteristic pattern of poly-ubinquinated Pol II in
infected cells [71]. As ubiquitination is one of the well known
markers for transcriptionally arrested Pol II [72], we believe the
modification of Pol II in infected cells might be relevant for viral
RNA production [73].
Induction of pro-inflammatory cytokines and
chemokines in primary human cells
We and others previously demonstrated that human H5N1
viruses are potent cytokine and chemokine inducers [20,21,22,23].
Subsequent studies further demonstrated that some of the viral
proteins from H5N1 viruses might regulate cytokine inductions
[20,74]. To test whether viral polymerase activity might have
effects on cytokine/chemokine expressions, representative H1N1
WSN mutants with a weak (AMMM) or a strong (MAMM)
polymerase activity were characterized in different primary cell
culture models. In addition, a weak (WSN) and a strong (Indo5)
cytokine inducer were included as controls. As shown in Fig. 5A,
the MAMM mutant was a strong stimulus to primary macro-
phages and the TNF-a, IFN-b, RANTES and IP-10 gene
expressions were found to be higher than those induced by the
positive H5N1 control (t-test, p,0.05). By contrast, the AMMM
Figure 2. Polymerase activity of vRNPs with chimeric PB1.
Various combinations of chimeric PB1 (Mutants 1 to 4, right panel)
derived from mammalian (hatched bar) and avian (solid bar) PB1 were
tested in the luciferase reporter assay in 293T cells incubated at 37uC.
The length of PB1 fragment in each region was indicated. The effect of
these chimeric PB1 on vRNP in a WSN (left top panel) or Indo5 (left
bottom panel) background were shown. The activities of the wild-type
control in the corresponding backgrounds were set as 100% for
references.
doi:10.1371/journal.pone.0005658.g002
Chimeric Influenza vRNPs
PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5658
mutant behaved similar to the WSN control. The cytokine/
chemokine gene expressions were positive correlated with the
amount of viral mRNA produced in the infected cells (Pearson’s
correlations, p,0.05). Culture supernatants from one of these
triplicate experiments were also checked for the TNF-a, IP-10 and
RANTES protein concentrations by ELISA and the MAMM-
infected cells were found to secrete high levels of these proteins as
expected (Table 1).
In MAMM-infected primary pneumocytes, similar gene expres-
sion patterns were observed, except TNF-a was not detectable as
expected [23] (Fig. 5B and data not shown). In summary, these
results suggested that the polymerase activity correlate with the
cytokine and chemokine inductions.
Virus with a strong polymerase activity is more ready to
generate adaptive mutations under a selection pressure
As the influenza viral polymerase lacks a proofreading activity,
the enhanced polymerase activity of the MAMM mutant might
allow the virus to generate more mutated viral RNA segments or
quasispecies in infected cells. We reasoned that this might enhance
the adaptive potential of the mutant. If it was the case, it would be
easier for the MAMM to cope with a new selection pressure. To
test this hypothesis, we serially passaged the MAMM mutant and
the wild-type virus in the presence of a NA inhibitor, oseltamivir.
We initially determined the drug concentration that was able to
reduce the viral titre by ,2 log PFU/ml. Under this selected drug
concentration, the MAMM virus had a 2 log-unit reduction of
viral titre in the early passages (Fig. 6A). Strikingly, the MAMM
virus was started to restore its fitness in the subsequent passages
(Fig. 6A). From two independent experiments, the viral titres of the
MAMM mutant at the late passage were about 15–30 times higher
than those found in the early passages. By contrast, the viral titres
of the wild-type control from all the studied passages remained low
(Fig. 6A). These results suggested that progeny viruses from the
MAMM mutant might contain adaptive mutation(s) to counteract
the inhibitory effect of the NA inhibitor.
Passaged MAMM mutants from two independent trials were
plaque purified (Fig. 6B, N = 9). As oseltamivir is known to induce
compensatory mutations in the HA and NA viral segments [75],
we therefore sequenced the ORFs of these segments. Apart from a
few sporadic mutations in some of these viruses, no consistent
mutation or mutational hotspot was identified in the HA or in the
globular head of NA. However, all of these ‘‘escape’’ MAMM
progeny viruses were found to contain mutations in the NA stalk
region (Fig. 6B). Two representative mutants from each trial were
selected and tested for their susceptibilities to the drug. As shown
in Fig. 6B, the studied escaped mutants had IC50 values of
oseltamivir about 11 to 21 times higher than those of the controls.
These results suggested the potential evolutionary advantages for
an influenza virus with a strong polymerase activity.
Discussion
In this study, we established a statistical method to study the
relative importance of different viral/non-viral factors on the viral
polymerase activity. In addition, we demonstrated that the
potential implications of enhanced viral polymerase activity to
human health.
Using WSN and Indo5 as prototype viruses, vRNPs with all 16
possible constellations were tested for their polymerase activities. We
primary focused on the factors which had the highest impacts on the
polymerase activity. It was demonstrated that both WSN PB2 and
Indo5 PB1 could enhance polymerase activity. Besides, the
temperature and the origin of the host were found to have a big
influence on viral polymerase activities as expected [30,58,59]. Our
statistical analysis revealed that the PB2-PB1 combination has
pronounced effects in our system. Viral polymerases with the WSN
PB2-Indo5 PB1 pair were found to have exceptionally high
polymerase activities in all the studied conditions. By contrast, Indo5
PB2 and WSN PB1 subunits were found to be highly incompatible.
To determine whether a similar PB2-PB1 interaction effect could be
detected in other human-avian recombinant vRNPs, we also
analyzed data from other similar systematic vRNPs analysis
[26,29,76]. Our data were in good agreement with the re-interpreted
data from two of these previous studies involving recombinant vRNPs
derived from human and HP avian strains (H7N1-H1N1 and H5N1-
H3N2 pairs) [26,29]. In these two previous studies, vRNPs with the
human PB1-avain PB2 pair were shown to have the highest
polymerase activity (Fig. S3). Beside, the introduction of PB1 from
a low pathogenic avian H2 virus (A/Mallard/NY/-6750/78) to a
human viral polymerase complex was also previously shown to
stimulate the viral polymerase activity [26,29]. Hence, these results
indicated that the PB2-PB1 interaction effect could be found in other
Figure 3. Luciferase reporter assay for influenza viral polymerase activity. Polymerase activities (mean6SE) of recombinant vRNPs
generated in CEF cells at 37uC are as shown.
doi:10.1371/journal.pone.0005658.g003
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recombinant human-avian vRNPs. On the other hand, Varich et al [77]
studied the gene constellations of reassortants between a mammalian
H1 and an avian H4. Of 11 isolates that were shown to have a
heterologous PB2-PB1 combination in this previous study, 9 of them
were found to have a mammalian PB2-avian PB1 gene constellation.
Chen et al also studied recombinants derived from an avian
H5N1virus and a human H3N2 virus [26]. In this previous report,
62.5% (10 out of 16) of mammalian PB2-avian PB1 recombinants
were shown to have efficient virus replications. By contrast, for
recombinant viruses with other PB2-PB1 combinations, only 40% of
them could replicate in an efficient manner. These results further
suggested that vRNPs with the mammalian PB2-avian PB1
combination might be beneficial to some viral strains for robust
virus replication.
It should be noted that, however, the PB2-PB1 interaction effect
might only applied to a subset of recombinant vRNPs. One should
not conclude the findings of this study as a universal phenomenon
for all influenza viruses. Other factors, such as the origin of NP or
PA, were found to be a critical determinant in controlling the
polymerase activity [26,76]. These results demonstrated that the
relative importance of these controlling factors vary between
strains. It is worth to mention that all of these previous
investigation mainly used the raw data to identify a single viral
factor that has the most prominent effect to the polymerase activity
[26,29,32,35,59,76,78,79]. Hence, little is known about the
possible interaction effect between these biological or other
physical parameters. Using a statistical method, we did not only
able to determine the effect of a particular viral polymerase
Figure 4. Characterization of recombinant viruses with chimeric polymerase complexes. The origins of PB2, PB1, PA and NP in each
recombinant virus was as shown (A= avian, M=mammalian). A) Plaque size (mean6SE) of the wild type (MMMM) and recombinant viruses in MDCK
cells at 72 hours post-infection. B) Growth properties of the WSN (MMMM) and recombinant viruses in MDCK cells. The number of infectious progeny
viral particles generated from MDCK cells infected with the corresponding virus at a MOI of 0.01 was determined by standard plaque assay. Mutant
AMAA and AMMM were significantly attenuated (ANOVA, p,0.05). *At 8 hours post-infection, the amounts of infectious progeny of MAAA and
MAMM were significantly higher than the wild type control (t-test, p,0.05). C) NA-specific primer extension assays. Total RNA from MDCK cells
infected with influenza virus at a MOI of 2 was harvested at 6 hours post-infection. Signals for the mRNA, cRNA and vRNA were as shown. D) Western
blot analysis of influenza PA and cellular Pol II from infected MDCK cells. Total cell lysates from cells infected at 2 MOI were harvested at 6 hours post-
infection. Signals for PA and ubiquitinated (Ubi-Pol II), hyperphosphorylated (IIo) and hypophosphorylated (IIa) Pol II were indicated. b-actin was used
as a control. The PA level of the MAMM mutant was more abundant than the wild type (MMMM), a further illustration of the faster transcription
kinetics of this chimeic vRNP. The experiment was repeated three times with comparable results.
doi:10.1371/journal.pone.0005658.g004
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Figure 5. Cytokine and chemokine gene expression profiles (mean6SE) from primary human macrophages (A) and pneuomocytes
(B). Total RNA from cells infected at a MOI of 2 was harvested at the indicated time points and tested by the corresponding quantitative RT-PCR
assays as indicated. The data were the averages of triplicate assays. The recombinant viruses used in the experiments were as shown.
doi:10.1371/journal.pone.0005658.g005
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Table 1. Quantitation of TNF-a, IP-10 and RANTES in culture supernatants from infected macrophages collected at different post-
infection time points.
Virus TNF-a (pg/ml) IP-10 (pg/ml) RANTES (pg/ml)
Time of postinfection Time of postinfection Time of postinfection
3 hr 6 hr 8 hr 3 hr 6 hr 8 hr 3 hr 6 hr 8 hr
MOCK U U U U U U 1 4 U
WSN U U 28 U U U 2 11 44
MAMM U 769 1032 U 75 123 U 100 167
AMMM U U U U U U 4 17 24
Indo5 U 143 391 U U 128 1 36 106
U: undetectable.
doi:10.1371/journal.pone.0005658.t001
Figure 6. Serial passage of the MAMM mutant in the presence of oseltamivir. A) Viral titers in culture supernatants. The wild type and
MAMM mutant were serially passaged in MDCK cells in the presence of oseltamivir. The viral cultures were harvested at 72 hr post-infection and the
supernatant from passages 1, 3, 5 and 7 were titrated by standard plaque assays. A representative data set from duplicated experiments was shown.
B) Protein sequence of the NA stalk. The passage histories and NA sequences from the parental controls, passaged controls and MAMM escape
mutants were as shown. The IC50 of oseltamivir towards these viruses were presented.
doi:10.1371/journal.pone.0005658.g006
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subunit on the viral polymerase activity, but also identified the
‘‘interaction effects’’ that might have a great impact to the vRNP
activity. Furthermore, we might use this statistical approach to
rank the relative importance of these factors or interaction effects
to the viral RNA transcription and replication. It is expected that
our new analytical approach might allow systematic studies of
different recombinant vRNPs, thereby leading to a better
understanding the factors or features that might be critical for
efficient viral RNA synthesis.
In this study, MAMM-infected cells were found to have a much
reduced Pol IIa protein expression. As the Pol IIa protein level is
negatively correlated with the viral RNA transcription and
replication [69], our findings suggested that this specific PB2-PB1
combination is more capable of forming transcriptionally active
polymerase complexes. PB1 and PB1-containing protein complexes
(i.e. PB2-PB1, PB1-PA and PB2-PB1-PA) were previously shown to
bind to various cellular factors [80,81,82,83]. It is possible that the
avian PB1 and human PB1 might have different affinities to these
proteins, thereby affecting the viral polymerase complex assembly.
However, we do not exclude other possibilities which might help to
explain this synergistic effect. Further investigations to address these
issues are required.
Previous studies demonstrated that the virulence of a HP H5N1
virus might correlate with the polymerase activity [78]. Here, we
demonstrated that a H1N1 with a robust vRNP polymerase could
induce hypercytokinemia in primary human cells. The cytokine
levels induced by this H1N1 mutant were even higher than those
from H5-infected cells. Our results indicated that the polymerase
activity might be positively correlated to the cytokine gene
expressions. It is of interest to study how the MAMM virus can
stimulate the cytokine gene expressions. Specifically, it is not
known whether the cytokine gene expressions in the MAMM-
infected cells were trigged by the enhanced viral polymerase
activity or by the increased amount of viral RNA. Influenza viral
RNA is known to activate RIG-I and PKR [84]. Further
characterizations of these proteins from the MAMM-infected cells
might help to better understand this issue. Nonetheless, the high
cytokine induction phenotype of the MAMM mutant in human
macrophages and pneumocytes is relevant to the pathogenesis of
human influenza virus infections.
Using a NA inhibitor to impose a moderate selection pressure to
the viruses, the MAMM mutant was found to be more capable of
restoring its replication fitness than the wild type. The MAMM
escape mutants were confirmed to have an increased resistance to
the NA inhibitor and mutations in the NA stalk region. The NA
stalk is known to affect the NA activity and viral lifecycle [85,86].
Introducing point mutations in the NA stalk were previously
shown to affect the NA activities [87]. It should be noted that these
viruses were intentionally passaged in a suboptimal inhibitory
concentration— a condition which allowed both the wild-type and
MAMM viruses to yield reasonable viral titers (,106 PFU/ml). It
is possible that compensatory mutations other than those
previously described resistance mutations [75] might be generated
under this less stringent condition. Further characterizations of
these escape mutants are required to elucidate the mechanism
responsible for this phenomena. In addition, the fidelity of these
recombinant viral polymerase complexes is needed to be fully
characterized. Irrespective of the underlying mechanisms account
for these observations, our results demonstrated that there is an
advantage for influenza viruses to acquire a robust vRNP to cope
with a new selection pressure.
The PB1 found in the pandemic human H2 or H3 is of avian
origins. It is tempting to speculate that the introduction of avian
PB1 in these pandemic reassortants might also enhance the
polymerase activities of these viruses, thereby increasing the
adaptive potential of these viruses. If this hypothesis was correct, it
would be easier for these reassorted viruses to generate adaptive
mutations in a new host. Further studies on different viral vRNPs
are needed to test this hypothesis.
Taken together, we described the compatibility between avian
and mammalian polymerase subunits. Viral polymerase complexes
with a WSN PB2 and an Indo5 PB1 were shown to have strong
polymerase activities. More importantly, we demonstrated that
vRNPs with a strong polymerase activity might be of human
health concern. First, this enhanced polymerase activity might
induce hypercytokinemia in human cells. Besides, viruses with
robust polymerase complexes might be more capable of creating
adaptive mutations under a selection pressure. Our findings might
add another dimension for identifying influenza viruses of
pandemic/zoonotic potential.
Supporting Information
Table S1 Full factorial analysis of the relative Importance of the
incubation temperature and the origin of PB2, PB1, PA, and NP
on influenza viral polymerase activity.
Found at: doi:10.1371/journal.pone.0005658.s001 (0.37 MB EPS)
Table S2 Full factorial analysis of the relative importance of the
origin of PB2, PB1, PA, NP, and cell on influenza viral polymerase
activity.
Found at: doi:10.1371/journal.pone.0005658.s002 (0.37 MB EPS)
Figure S1 Polymerase activity of vRNPs with chimeric PB2 in
293T cells. Chimeric PB2 (upper panel) derived from the
mammalian (open bar) and avian (solid bar) PB2 were tested in
the luciferase reporter assay (lower panel) at 37uC. The length of
PB2 fragment in each region was indicated. The activities of the
wild-type Indo5 vRNP was set as 100%. Chimeric PB2 with its C-
terminal 1/3 derived form WSN (iiw, iww or wiw) was able to
stimulate the polymerase activity to a level which is comparable to
WSN control (www).
Found at: doi:10.1371/journal.pone.0005658.s003 (0.55 MB EPS)
Figure S2 Growth properties of the WSN (MMMM) and
polymerase mutants at 32uC (A) and 40uC (B). The numbers of infec-
tious progeny viral particles generated from MDCK cells infected at a
MOI of 0.01 were determined by standard plaque assays.
Found at: doi:10.1371/journal.pone.0005658.s004 (0.44 MB EPS)
Figure S3 Relative polymerase activities of avian-mammalian
chimeric vRNPs. Data from Chen et al (A) and Naffakh et al (B)
were reorganized and presented in a format used in this study
[26,29]. The origins of PB2, PB1, PA and NP in each recombinant
vRNP were as shown (A = avian, M = mammalian). Viral strains
used in these studies were shown as indicated.
Found at: doi:10.1371/journal.pone.0005658.s005 (0.63 MB EPS)
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